Protodigm Uses AI to Suggest All Possible Avenues a Drug Could Go
Mike Rea, is founder of Protodigm, a contract skunkworks lab specializing in minimizing the risk of drug development by avoiding bias, premature special...
5240 articles
Mike Rea, is founder of Protodigm, a contract skunkworks lab specializing in minimizing the risk of drug development by avoiding bias, premature special...
As the most common type of non-cancerous tumors in women of reproductive age, uterine fibroids can cause physical symptoms, including heavy menstrual bl...
Steve Romano, MD, Executive Vice President and Chief Scientific Officer at Mallinckrodt Pharmaceuticals discusses the results of their pivotal Phase 3 ...
Nearly 1.8 million people globally die of lung cancer each year, more than the second and third most deadly cancers combined (colorectal and stomach can...
Chris Anzalone, PhD, President and CEO of Arrowhead Pharmaceuticals discusses new positive patient-level data from their AROAAT2002 global Phase 2 study...
Arezou Khosroshahi, MD, Associate Professor of Medicine at Emory University discusses the enrollment of the first patient in Horizon Therapeuti...
James Tursi, MD, Chief Scientific Officer of Ferring Pharmaceuticals discusses developments in microbiome-based therapeutics for the treatment of recurr...
Kaveh Safavi, Global Health Lead of Accenture Health, discusses the findings from their 2021 Digital Health Tech Vision report that surveyed 399 healthc...
Girish Navani, CEO and Cofounder of eClinicalWorks, a leader in healthcare IT solutions discusses PRISMA, the healthcare industry's first health informa...
Larry Edwards, MD, MACP, MACR, rheumatologist and Chairman of the Gout Education Society discusses managing gout during the summer, with travel and g...